Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEN101 in advanced solid tumors
NCT05831033Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2023
- Primary completion
- Feb 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BEN-101 in solid tumor, sponsored by Shanghai General Hospital. Primary endpoint: Adverse Events at 6 months. Started May 2023; status: recruiting.
02
Drugs
BEN-101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05831033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05831033.